Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study.
作者信息
Amabile Simone, Tonella Luca, Rubatto Marco, Argenziano Giuseppe, Babino Graziella, Frascione Pasquale, Dika Emi, Giacomelli Luca, Parodi Aurora, Quaglino Pietro
机构信息
Dermatologic Clinic, University of Turin Medical School, Turin, Italy.
Dermatology Unit, University of Campania, Naples, Italy.
出版信息
Eur J Dermatol. 2022 Feb 11;32(1):126-7. doi: 10.1684/ejd.2022.4198.
Abstract
摘要
相似文献
1
Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study.使用角质计评估BRAF/MEK抑制剂治疗的转移性黑色素瘤患者的水合指数：一项前瞻性研究。
Eur J Dermatol. 2022 Feb 11;32(1):126-7. doi: 10.1684/ejd.2022.4198.
2
[Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].[MEK抑制剂和BRAF抑制剂靶向治疗转移性皮肤黑色素瘤的眼部毒性]
J Fr Ophtalmol. 2022 Jun;45(6):612-618. doi: 10.1016/j.jfo.2021.08.005. Epub 2022 Apr 29.
3
The role of MEK inhibitors in the treatment of metastatic melanoma.MEK 抑制剂在转移性黑色素瘤治疗中的作用。
Curr Opin Oncol. 2014 Mar;26(2):196-203. doi: 10.1097/CCO.0000000000000050.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.MEK 抑制剂在转移性黑色素瘤和实体瘤治疗中的应用。
Am J Clin Dermatol. 2017 Dec;18(6):745-754. doi: 10.1007/s40257-017-0292-y.
6
Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.52 例接受 BRAF-V600+MEK 抑制剂治疗的晚期黑色素瘤患者的疾病进展特征和结局。
Dermatology. 2018;234(3-4):92-98. doi: 10.1159/000490891. Epub 2018 Aug 15.
7
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.BRAF、MEK 和 CDK4/6 抑制剂的免疫调节作用：对联合靶向治疗和免疫检查点阻断治疗黑色素瘤的意义。
Front Immunol. 2021 May 7;12:661737. doi: 10.3389/fimmu.2021.661737. eCollection 2021.
8
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.系统性BRAF/MEK抑制剂作为转移性结膜黑色素瘤的一种潜在治疗选择
Ocul Oncol Pathol. 2017 Jul;3(2):133-141. doi: 10.1159/000452473. Epub 2016 Dec 8.
9
Prognostic value of total metabolic tumour volume and therapy-response assessment by [F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.总代谢肿瘤体积及[F]FDG PET/CT对BRAF/MEK抑制剂治疗的转移性黑色素瘤患者的治疗反应评估的预后价值
Eur Radiol. 2022 May;32(5):3398-3407. doi: 10.1007/s00330-021-08355-1. Epub 2021 Nov 15.
10
Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.真心话大冒险：在转移性黑色素瘤患者发生急性间质性肾炎后切换 BRAF/MEK 抑制剂——病例报告及文献复习。
Acta Clin Belg. 2023 Jun;78(3):215-222. doi: 10.1080/17843286.2022.2114684. Epub 2022 Aug 23.
本文引用的文献
1
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.COLUMBUS 研究中耐受性和总生存期更新：随机 3 期试验中比较 encorafenib 加 binimetinib 与 vemurafenib 或 encorafenib 治疗 BRAF V600 突变型黑色素瘤患者的里程碑分析结果
Eur J Cancer. 2020 Feb;126:33-44. doi: 10.1016/j.ejca.2019.11.016. Epub 2020 Jan 2.
2
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
3
Cutaneous Complications of Targeted Melanoma Therapy.靶向黑色素瘤治疗的皮肤并发症
Curr Treat Options Oncol. 2016 Nov;17(11):57. doi: 10.1007/s11864-016-0434-0.
4
EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: clinical scoring systems.欧洲化妆品原料协会（EEMCO）关于干性皮肤（皮肤干燥症）和鱼鳞病评估的指南：临床评分系统
Skin Res Technol. 1995 Aug;1(3):109-14. doi: 10.1111/j.1600-0846.1995.tb00029.x.
5
Incidence and risk of xerosis with targeted anticancer therapies.靶向抗癌治疗的干燥症发生率和风险。
J Am Acad Dermatol. 2015 Apr;72(4):656-67. doi: 10.1016/j.jaad.2014.12.010. Epub 2015 Jan 27.
6
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.BRAF 和 MEK 联合抑制与单独 BRAF 抑制治疗黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
7
Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.化疗药物引起的皮肤不良反应，第2部分：BRAF抑制剂、MEK抑制剂和伊匹单抗。
Semin Cutan Med Surg. 2014 Mar;33(1):40-8. doi: 10.12788/j.sder.0061.
8
Multicentre comparison of skin hydration in terms of physical-, physiological- and product-dependent parameters by the capacitive method (Corneometer CM 825).应用电容法（Corneometer CM 825），通过物理参数、生理参数和产品相关参数对皮肤水合作用进行多中心比较。
Int J Cosmet Sci. 2003 Apr;25(1-2):45-53. doi: 10.1046/j.1467-2494.2003.00172.x.
9
Tape-stripping method in man: comparison of evaporimetric methods.人体胶带剥离法：蒸发测定法的比较
Skin Res Technol. 2007 May;13(2):207-10. doi: 10.1111/j.1600-0846.2007.00218.x.
Zotero 插件